EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 384 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mom Is Outraged After Finding Out Her Mother-In-Law Changed The Baby’s... May 6, 2019 At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... February 27, 2024 Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... December 2, 2019 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Load more HOT NEWS Can Using a Microwave Cause Cancer? ESMO Raises Key Issues on Cancer Prevention and Care at the... What Are Patient-Reported Outcomes and Why Are They Important in Cancer... Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will...
